Skip to main content
Videos

Impact of BRCA1 and RAD15 Methylation on Maintenance Olaparib Plus Bevacizumab Efficacy in Ovarian Cancer


At the 2023 ASCO Annual Meeting, Helene Blons, PhD, PharmD, European Georges Pompidou Hospital, discusses results from an abstract addressing the impact of BRCA1 and RAD51 methylation on the efficacy of olaparib plus bevacizumab maintenance treatment, from the PAOLA-1/ENGOT-ov25 trial.

Source:

Blons H, Abdelli J, Taly V, et al. BRCA1 and RAD51 methylation impact on outcome in patients with advanced ovarian cancer: A PAOLA-1 ancillary study. Presented at 2023 ASCO Annual Meeting; June 2-6, 2023; Chicago, IL. Abstract 5559

© 2023 HMP Global. All Rights Reserved.
Any views and opinions expressed are those of the author(s) and/or participants and do not necessarily reflect the views, policy, or position of INSERT BRAND or HMP Global, their employees, and affiliates.